P50 OVERALL SURVIVAL ADVANTAGE OF MONOCLONAL ANTIBODIES BASED-TREATMENTS IN MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION

MLA

C. Nozzoli, et al. “P50 Overall Survival Advantage of Monoclonal Antibodies Based-Treatments in Multiple Myeloma Patients Relapsed After Allogeneic Stem Cell Transplantation.” HemaSphere, vol. 7, no. S2, May 2023, p. 38. EBSCOhost, https://doi.org/10.1097/01.HS9.0000936328.14674.49.

APA

C. Nozzoli, M. Pucillo, M. Martino, L. Giaccone, A. Rambaldi, E. Benedetti, D. Russo, N. Mordini, P. Bernasconi, S. Mangiacavalli, P. Pioltelli, P. Carluccio, P. Galieni, M. Ladetto, S. Sica, M. Isola, M. De Martino, E. Oldani, E. Degrandi, … on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). (2023). P50 Overall Survival Advantage of Monoclonal Antibodies Based-Treatments in Multiple Myeloma Patients Relapsed After Allogeneic Stem Cell Transplantation. HemaSphere, 7(S2), 38. https://doi.org/10.1097/01.HS9.0000936328.14674.49

Chicago

C. Nozzoli, M. Pucillo, M. Martino, L. Giaccone, A. Rambaldi, E. Benedetti, D. Russo, et al. 2023. “P50 Overall Survival Advantage of Monoclonal Antibodies Based-Treatments in Multiple Myeloma Patients Relapsed After Allogeneic Stem Cell Transplantation.” HemaSphere 7 (S2): 38. doi:10.1097/01.HS9.0000936328.14674.49.